Metagenomi Therapeutics, Inc.
MGX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001785279
In the last 90 days, Metagenomi Therapeutics, Inc. insiders filed 1 open-market purchase and 3 sales; 43 institutions reported holding it in 13F filings for Q2 2026, worth $7.45M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Metagenomi Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 54 | 1 | 67 | +14 |
| Shares | 12.2M | 420.2K | 11.7M | −105.1K (−0.9%) |
| Value | $49.6M | $1.71M | $25.3M | −$22.5M (−47.1%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (23)
Institutions that held Metagenomi Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (9)
Institutions that held Metagenomi Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Eventide Asset Management, LLC | 583,041 | $2.38M |
| Artal Group S.A. | 300,000 | $1.22M |
| Frazier Life Sciences Management, L.P. | 245,692 | $1.00M |
| Point72 Asset Management, L.P. | 99,002 | $403.9K |
| Hudson Bay Capital Management LP | 17,000 | $69.4K |
| XTX Topco Ltd | 16,244 | $66.3K |
| Bramshill Investments, LLC | 15,500 | $63.2K |
| Cerity Partners LLC | 10,000 | $40.8K |
| Qube Research & Technologies Ltd | 1,053 | $4.30K |
Not filed for Q3 2024 yet (1)
Institutions that held Metagenomi Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 420,242 | $1.71M |